Get the Stockscreener App
0.00
100.00%
-135.07
Apogee Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$135.07
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$10.20B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
0.00
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$135.09
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
0.00 | 10.20B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
521.67 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.05 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.85 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.45 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.04 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Fairmount Funds Management LLC Exits Apogee Therapeutics Inc (APGE) Position Entirely - GuruFocus
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment - AD HOC NEWS
Michael Henderson: A New Chapter Begins for Apogee Therapeutics With AbbVie - Oncodaily
Fairmount Funds Management Exits Apogee Therapeutics (NASDAQ: APGE) Following $135.11 Per Share Merger Payout - Kalkine Media
Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting - The Globe and Mail
AbbVie-owned Apogee Therapeutics (APGE) pulls unsold stock - Stock Titan
Apogee Therapeutics (APGE) director-linked funds fully exit in AbbVie deal - Stock Titan
Apogee Therapeutics (APGE) CMO cashes out stock and options in AbbVie deal - Stock Titan
Apogee (APGE) director’s shares and options cashed out in AbbVie deal - Stock Titan
Apogee merger pays $135.11 per share in cash | APGE SEC FilingForm SCHEDULE 13D/A - Stock Titan
AbbVie Completes $10.9 Billion Acquisition Of Apogee Therapeutics - Pulse 2.0
AbbVie (ABBV) Completes Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Finalizes $10.9 Billion Acquisition of Apogee Therapeutics, Initiates Nasdaq Delisting - Kalkine Media
Biotech Stocks To Follow NowSeptember 3rd - MarketBeat
AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline - Dermatology Times
AbbVie Completes Acquisition of Apogee Therapeutics - Investing News Network
Apogee Therapeutics (Nasdaq: APGE) loses its Nasdaq listing - Stock Titan
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - Seeking Alpha
Apogee Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from S&P TMI Index - marketscreener.com
Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from NASDAQ Composite Index - marketscreener.com
APGE Stock Price, Quote & Chart - ChartMill
Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from NASDAQ Biotechnology Index - marketscreener.com
Apogee Therapeutics stock hits all-time high at 134.89 USD - Investing.com
Apogee Therapeutics Market Sentiment - Benzinga España
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighShould You Buy? - MarketBeat
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal - TradingView
What Will Apogee Therapeutics (NASDAQ:APGE) Say on Trials? - Kalkine Media
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO Dambkowski sells $737k in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $737k in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liquidity Mapping Around (APGE) Price Events - news.stocktradersdaily.com
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Truist Financial Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Raises Target Price to $135 - Moomoo
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research - MarketBeat
APGE Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
BTIG Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal By Investing.com - Investing.com South Africa
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com Nigeria
Apogee Therapeutics Directors Execute Stock Options, Increasing Holdings - Kalkine Media
Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options - Stock Titan
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apogee Therapeutics Inc Stock (APGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Aug 05 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
173,998 |
| Dambkowski Carl | Chief Medical Officer |
Aug 05 '26 |
Sale |
134.17 |
5,500 |
737,935 |
168,498 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
Jul 08 '26 |
Sale |
133.63 |
20,000 |
2,672,600 |
995,987 |
| Dambkowski Carl | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
183,373 |
| Dambkowski Carl | Chief Medical Officer |
Jul 01 '26 |
Sale |
132.74 |
5,500 |
730,070 |
177,873 |
0.40%
4.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):